Clinical Trials Logo

Clinical Trial Summary

Stenotrophomonas maltophilia is a multi-resistant Gram-negative bacillus and is an opportunistic pathogen. Stenotrophomonas maltophilia infections are associated with a significant morbidity and mortality, particularly in immunocompromised patients. The mortality of infections (bacteremia, pneumonia) related to Stenotrophomonas maltophilia is variable and is estimated between 21 and 69%. Stenotrophomonas maltophilia pneumopathies have been mainly described in patients hospitalized in intensive care and benefiting from mechanical ventilation. The existence of immunosuppression seems to be a risk factor for the transition from Stenotrophomonas maltophilia pulmonary colonization to Stenotrophomonas maltophilia pulmonary infection. The reference treatment for Stenotrophomonas maltophilia-associated pneumonia is the combination of trimethoprim and sulfamthoxazole, a molecule that lung transplant patients routinely receive as a preventive treatment for Pneumocysitis jirovecii infection. There is no consensus on the value of routine dual-antibiotic therapy, and it varies from one center to another and from one country to another. The main objective is to compare the clinical-microbiological evolution of lung transplant patients treated for Stenotrophomonas maltophilia pneumopathy according to the prescription of a mono- or bi-antibiotherapy. The secondary objective is to evaluate the resistance rate of Stenotrophomonas maltophilia strains isolated from respiratory samples according to the anti-pneumocystis prophylactic molecule received by the patient.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05193058
Study type Observational
Source Groupe Hospitalier Paris Saint Joseph
Contact Benoit PILMIS, MD
Phone 144127820
Email bpilmis@ghpsj.fr
Status Recruiting
Phase
Start date November 22, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05047406 - Bacillus Clausii in Liver Transplantation Phase 2
Completed NCT02463214 - Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients N/A
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Completed NCT01808456 - Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant. Phase 4
Suspended NCT01301118 - Graft Take and Microbiology in Burns N/A
Completed NCT00610961 - Induction Related BK Viremia in Renal Transplant Patients Phase 4
Recruiting NCT05215327 - High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients Phase 2
Unknown status NCT01983761 - Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation Phase 1/Phase 2
Active, not recruiting NCT02811835 - TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN) N/A
Completed NCT01471444 - Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase 3
Enrolling by invitation NCT01349738 - Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants N/A
Terminated NCT00473824 - Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation Phase 2
Completed NCT00177801 - Organ Transplant Infection Prevention and Detection Project Phase 4
Completed NCT01276457 - Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients Phase 3
Completed NCT02328963 - Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Phase 4
Recruiting NCT04320303 - CMV Infection and Immune Intervention After Transplantation N/A
Active, not recruiting NCT01295645 - Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis Phase 2
Completed NCT02329808 - Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
Completed NCT01471067 - Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Phase 1
Recruiting NCT04579471 - Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study